End-to-End CRO Platform

The Cyagen End-to-End CRO Platform offers a comprehensive suite of advanced preclinical solutions, specializing in customized gene-edited models, humanized mice, iPSCs, and robust pharmacodynamic testing across all therapeutic modalities. By optimizing and accelerating gene therapy workflows through dedicated AAV design, manufacturing, and evaluation services, we empower global researchers to seamlessly advance breakthroughs from discovery to IND.

Cyagen Preclinical CRO Services

Backed by a highly experienced technical team and a deep portfolio of validated disease models, Cyagen delivers robust in vivo and in vitro pharmacology services to characterize drug efficacy, PK/PD profiles, and biomarker responses. We specialize in translating complex therapeutic concepts into reliable preclinical data, offering extensive therapeutic expertise across immunology, neurology, metabolic diseases, ophthalmology, oncology, and rare diseases. Our integrated workflows are engineered to streamline rigorous safety and functional evaluation, providing global biopharmaceutical partners with the high-precision data required to confidently advance novel candidates toward clinical development.

Therapeutic Area

Our specialized scientific team brings years of peer-reviewed project experience to your specific pipeline challenges, optimizing study designs for high-impact therapeutic areas:

Neuroscience

CRO Solutions accelerating breakthroughs in Alzheimer’s, Parkinson’s, and other neurological disorders, as well as in blood-brain barrier (BBB) transfer research.

Ophthalmology

Specialized preclinical models and CRO solutions advancing research in AMD, RP, glaucoma, and other ocular disorders.

Oncology

Advanced humanized PBMC and HIS mouse models enabling robust immuno-oncology research and targeted therapy evaluation.

Metabolic & Cardiovascular Diseases

Genetic and diet-induced models driving innovation in metabolic and cardiovascular therapeutics.

Autoimmune & Inflammatory

Robust models and CRO solutions powering innovation in inflammatory and autoimmune disease studies.

Innovative Drug R&D

We provide comprehensive preclinical efficacy and safety studies that have successfully accelerated pipeline development for our biopharmaceutical partners. Our testing capabilities accommodate a wide range of drug modalities:

Antibody

Accelerate therapeutic antibody discovery with fully human antibody platforms, AI-powered analysis, functional screening, and in vivo validation.

Cell Therapy

Advance CAR-T, CAR-NK, and universal cell therapy programs with integrated support from antibody discovery and CAR design to cell engineering and in vivo efficacy testing.

Gene Therapy

Streamline gene therapy development with integrated solutions covering target discovery, AAV vector design, disease model generation, and in vivo efficacy validation.

ADC/AOC

De-risk targeted conjugate therapeutics with end-to-end ADC/AOC solutions spanning fully human antibody discovery, payload delivery assessment, in vitro assays, and humanized model validation.

Oligonucleotide Therapy

Support ASO, siRNA, and precision gene modulation programs with full-cycle CRO services from in vitro knockdown screening to translational in vivo validation.

INTEGRATED PRECLINICAL CAPABILITIES

From Therapeutic Expertise to Translational Execution

Across each therapeutic area, Cyagen combines validated disease models, custom gene-edited models, and integrated in vivo pharmacology services. From model selection and study design to efficacy evaluation and data analysis, our end-to-end platform helps researchers generate reliable preclinical data and advance promising therapeutic candidates with greater confidence.

Explore our models